Related Experiment Video
Updated: Jul 16, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Amplicon profiles in ovarian serous carcinomas
Kentaro Nakayama1, Naomi Nakayama, Natini Jinawath
1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
International Journal of Cancer
|March 14, 2007
Summary
High-grade serous ovarian carcinomas exhibit widespread DNA copy number changes, unlike low-grade tumors. Key oncogene amplifications, including CCNE1, were identified, offering insights into ovarian cancer pathogenesis.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Ovarian serous carcinoma is a lethal cancer with poorly understood molecular causes.
- Understanding DNA copy number alterations is crucial for elucidating its pathogenesis.
Purpose of the Study:
- To comprehensively analyze DNA copy number changes in high-grade and low-grade ovarian serous carcinomas.
- To identify specific genetic alterations associated with high-grade serous carcinoma development.
Main Methods:
- Genome-wide single nucleotide polymorphism array analysis on purified tumor cells.
- Dual-color fluorescence in situ hybridization (FISH) for amplicon validation.
- Comparison of genetic alterations between high-grade and low-grade serous tumors.
Main Results:
- High-grade serous carcinomas displayed widespread DNA copy number changes, contrasting with low-grade tumors.
- Frequent amplifications were observed in oncogenes like cyclin E1 (CCNE1), AKT2, Notch3, and PIK3CA.
- Specific loci including 12p13, 8q24, and 12q15 showed significant alterations in high-grade tumors.
Conclusions:
- This study provides the first comprehensive DNA copy number analysis in highly pure ovarian serous carcinoma.
- Identified genetic alterations, particularly oncogene amplifications, may hold significant biological and clinical implications for ovarian cancer.
- Findings contribute to a better understanding of the molecular etiology of ovarian serous carcinomas.
